GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Owner Earnings per Share (TTM)

Generex Biotechnology (Generex Biotechnology) Owner Earnings per Share (TTM) : 0.00 (As of Apr. 2021)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Generex Biotechnology's Owner Earnings per Share (TTM) ended in Apr. 2021 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Generex Biotechnology's Owner Earnings per Share (TTM) or its related term are showing as below:



GNBTQ's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Generex Biotechnology's Earnings per Share (Diluted) for the three months ended in Apr. 2021 was $-0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52. It's PE Ratio ratio for today is At Loss.

Generex Biotechnology's EPS without NRI for the three months ended in Apr. 2021 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52. It's PE Ratio without NRI ratio for today is At Loss.


Generex Biotechnology Owner Earnings per Share (TTM) Historical Data

The historical data trend for Generex Biotechnology's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Owner Earnings per Share (TTM) Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -2.20 0.46 0.04 -0.28

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.28 -0.15 -0.23 -0.05

Competitive Comparison of Generex Biotechnology's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Generex Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generex Biotechnology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generex Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Generex Biotechnology's Price-to-Owner-Earnings falls into.



Generex Biotechnology Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Generex Biotechnology's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -37.26
Depreciation, Depletion and Amortization 1.16
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.26
Change In Working Capital 29.63
Shares Outstanding (Diluted Average) 140.41

1. Start with "Net Income" from income statement. Generex Biotechnology's Net Income for the trailing twelve months (TTM) ended in Apr. 2021 was $-37.26 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Generex Biotechnology's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Apr. 2021 was $1.16 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Generex Biotechnology's Change In Deferred Tax for the trailing twelve months (TTM) ended in Apr. 2021 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.26 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Generex Biotechnology's 5-Year Average Maintenance Capital Expenditure = $0.26 Mil

5. "Change In Working Capital" is from cashflow statement. Generex Biotechnology's Change In Working Capital for the trailing twelve months (TTM) ended in Apr. 2021 was $29.63 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Generex Biotechnology's Shares Outstanding (Diluted Average) for the months ended in Apr. 2021 was 140.407 Mil.

Generex Biotechnology's Onwer Earnings Per Share for Apr. 2021 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -37.262 +1.163+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.256+29.625)/140.407
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.0002/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Generex Biotechnology Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus